Longitudinal evaluation of eltrombopag in paediatric acquired severe aplastic anaemia
Open Access
- 12 June 2020
- journal article
- letter
- Published by Wiley in British Journal of Haematology
- Vol. 190 (3), E157-E159
- https://doi.org/10.1111/bjh.16766
Abstract
No abstract availableThis publication has 13 references indexed in Scilit:
- Successful long‐term hematological and immunological reconstitution by autologous cord blood transplantation combined with post‐transplant immunosuppression in two children with severe aplastic anemiaPediatric Transplantation, 2018
- Aplastic AnemiaThe New England Journal of Medicine, 2018
- Updated Guidelines for the Treatment of Acquired Aplastic Anemia in ChildrenCurrent Oncology Reports, 2018
- Upfront eltrombopag monotherapy induces stable hematologic remission in pediatric patients with nonsevere idiopathic aplastic anemiaPediatric Blood & Cancer, 2018
- Eltrombopag Added to Standard Immunosuppression for Aplastic AnemiaThe New England Journal of Medicine, 2017
- First-line treatment for severe aplastic anemia in children: bone marrow transplantation from a matched family donor versus immunosuppressive therapyHaematologica, 2014
- Eltrombopag restores trilineage hematopoiesis in refractory severe aplastic anemia that can be sustained on discontinuation of drugBlood, 2014
- Acquired Aplastic Anemia in ChildrenPediatric Clinics of North America, 2013
- Excellent outcome of matched unrelated donor transplantation in paediatric aplastic anaemia following failure with immunosuppressive therapy: a United Kingdom multicentre retrospective experienceBritish Journal of Haematology, 2012
- Long-Term Outcome of Pediatric Patients with Severe Aplastic Anemia Treated with Antithymocyte Globulin and CyclosporineThe Journal of Pediatrics, 2008